EGFR/EGFRvIII inhibitor WSD0922-FU

{
  "id": "MLC-T-ONC-013274",
  "term": "EGFR/EGFRvIII inhibitor WSD0922-FU",
  "field": "Oncology and biomedicine",
  "definition": "A blood-brain-barrier (BBB) penetrable selective inhibitor of epidermal growth factor receptor (EGFR) and various EGFR mutations, including but not limited to the EGFR variant III (EGFRvIII) mutant form, with potential antineoplastic activity. Upon administration of EGFR/EGFRvIII inhibitor WSD0922-FU, this agent is able to penetrate the BBB and specifically targets, binds to and inhibits EGFR and specific EGFR mutations, which prevents EGFR/EGFR mutant-mediated signaling and leads to cell death in EGFR/EGFR mutant-expressing tumor cells. Compared to other EGFR inhibitors that are not able to penetrate the BBB, WSD0922-FU may have therapeutic benefits in brain tumors, such as glioblastoma (GBM) and metastatic CNS tumors. EGFR, a receptor tyrosine kinase (RTK) that is mutated in many tumor cell types, plays a key role in tumor cell proliferation and survival.",
  "synonyms": [
    "BBB penetrable EGFR/EGFRvIII inhibitor WSD0922-FU",
    "EGFR mutant inhibitor WSD0922-FU"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/egfr-egfrviii-inhibitor-wsd0922-fu/"
}